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ABSTRACT 
It has been shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors have pleiotropic effects and that human serum paraoxonase (PON1) 
inhibits the oxidative modification of low-density lipoprotein. We investigated the 
effects of pitavastatin on PON1 gene promoter activity and PON1 protein 
expression through the activation of mitogen-activated protein (MAP) kinase 
signaling cascades in cultured Huh7 cells. Both PON1 gene promoter activity 
and PON1 protein expression were elevated by pitavastatin stimulation. 
Pitavastatin phosphorylated p44/42 MAP kinase. The effects of pitavastatin on 
PON1 promoter activity and PON1 protein expression were attenuated by 
PD98059. The cotransfection of Sp1 expression vector increased PON1 
promoter activity, and mithramycin suppressed pitavastatin-enhanced PON1 
promoter activity. The latter activity was attenuated by cotransfection with the 
expression vector of sterol regulatory element-binding protein-2 (SREBP-2) with 
mutated p44/42 MAP kinase specific phosphorylation sites. Pitavastatin 
increased the Sp1-PON1 DNA complex and this effect was attenuated by 
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PD98059. These observations suggest that pitavastatin phosphorylates p44/42 
MAP kinase and then activates the transcription of PON1 gene and increases 
the PON1 protein expression in Huh7 cells. Furthermore, we speculate that 
pitavastatin affects both the phosphorylation of SREBP-2 and the Sp1 binding to 
PON1 DNA through the activation of p44/42 MAP kinase signaling cascade.  
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INTRODUCTION 
 Human serum paraoxonase (PON1) is an esterase that hydrolyzes 
aromatic carboxylic acid esters, organophosphates and carbonates. It is noted 
that PON1 associates with high-density lipoprotein (HDL) [1] and inhibits the 
oxidation of low-density lipoprotein (LDL) and HDL [2, 3]. PON1 knockout mice 
were unable to protect against the progression of atherosclerosis by feeding on 
a high fat and high cholesterol diet [4], and atherosclerotic lesion formation was 
decreased in PON1 transgenic mice [5].  We are included among researchers 
who have reported that PON1 activity is related not only to macroangiopathy, but 
also to microangiopathy, such as retinopathy and nephropathy in diabetic 
patients [6–8]. These reports indicate that PON1 has effects against oxidative 
disorders in vivo and also that it plays an important role in the suppression of the 
development and progression of atherosclerosis [9]. 
 A clinical trail has shown that 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors (statins) have various pleiotropic effects against 
atherosclerosis apart from their cholesterol-lowering action [10]. Anti-oxidation 
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has been suggested as one of the pleiotropic effects of statins [11]. Also, 
simvastatin has been reported to inhibit macrophage-dependent LDL oxidization 
[12], and atorvastatin to inhibit copper-derived LDL oxidization [13]. 
 Clinical studies showed that simvastatin normalized the lower enzyme 
activity of PON1 in patients with familial hypercholesterolemia [14] and that the 
statin increased the serum concentrations and activities of PON1 in patients with 
hypercholesterolemia [15]. We previously reported using a reporter gene assay 
method showing that pitavastatin enhanced the promoter activity of the PON1 
gene in HepG2 cells of a human hepatocellular carcinoma cell line and in human 
embryonic kidney 293 (HEK293) cells through a depletion of mevalonic 
acid-derived farnesyl pyrophosphate [16]. Deakin et al. reported that simvastatin 
increased sterol regulatory element-binding protein-2 (SREBP-2) binding to 
PON1 DNA, and that SREBP-2 up-regulated PON1 gene promoter activity in 
HepG2 cells [15]. SREBP-2 is a transcription factor that is a major regulator of 
cholesterol homeostasis and that is activated by cellular cholesterol depletion. It 
was recently demonstrated that SREBP-2 was linked to p44/42 
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mitogen-activated protein (MAP) kinase signaling cascade [17, 18]. On the other 
hand, statins regulate the induction of various proteins or genes through an 
activation of MAP kinase signaling cascades [19-21]. However, there have been 
no reports in related literature that MAP kinase signaling cascades are involved 
in PON1 protein expression or its promoter activation in human hepatocytes. 
 In the present study, we investigated whether pitavastatin stimulated PON1 
gene promoter activity and affected its protein expression through MAP kinase 
signaling cascades in cultured human hepatoma Huh7 cells in vitro. We showed 
that pitavastatin increased PON1 gene promoter activity and PON1 protein 
expression and that these effects were regulated by p44/42 MAP kinase 
signaling cascade.  
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MATERIALS and METHODS 
Cell culture and maintenance 
 Huh7 cells were cultured and maintained in Dulbecco's modified Eagle's 
medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% 
heat-inactivated fetal calf serum (FCS) (Life Technologies, Rockville, MD), 100 
U/ml penicillin (Life Technologies) and 20 μg/ml streptomycin (Life Technologies) 
in 90-mm plastic plates (Nunc, Roskilde, Denmark), and incubated at 37°C in 5% 
CO2. The cells were seeded into 90-mm tissue culture plates and routinely 
passaged every 3–4 days. These cells were seeded into 24-well plastic plates 
(Corning, Corning, NY) for luciferase assays and 6-well plastic plates (Nunc) for 
Western blotting. 
 
Treatment and reagents 
 Pitavastatin was gifted from Kowa Ltd. (Tokyo, Japan). PD98059 and 
U0126 were purchased from Promega (Madison, WI), and SP600125 and 
SB203580 from Sigma. All of the above reagents were dissolved in dimethyl 
 8 
sulfoxide (DMSO) (Nakarai Tesque, Kyoto, Japan) adjusted with DMEM to a 
final concentration of 0.1%. The medium of control wells was adjusted to 
0.1% DMSO. Plasmid constructs were transfected 120 min before treatment 
with each reagent for luciferase assay.  
 
Plasmid constructs and transfection 
 We used plasmid constructs with PON1 gene 5’-flanking regions for 
luciferase assay, as reported previously [22]. pGL3 luciferase reporter vectors 
(Promega) introduced DNA fragments of PON1 genes (–587/–6) 
(pGL3-PON1[587/-6]) were used in the present study. The number of DNA 
fragments is shown from the ATG start codon because of multi-transcription sites 
of the PON1 genes.   
 We used an expression vector of the specificity protein 1 (Sp1) for 
mammalian cells, as reported previously [16]. We also constructed an 
expression vector of SREBB-2 and a mutated form at the positions of major 
p44/42 MAP-kinase specific phosphorylation sites, whose Ser-432 and Ser-455 
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were substituted with Ala (pCL-SREBP-2 S432/455A) according to previous 
reports [18]. The mutated construct was made by using a mutagenesis kit 
(QuikChange Multi Site-Directed Mutagenesis Kit, Stratagene, La Jolla, CA) with 
specific oligos: 5’-AGAATGTCCTTCTGATGCACCCCCAGCCTCTG-3’ and 
5’-GACTCTGAGCCAGGAGCCCCTCTATTGGATGATGC-3’. (The underlined 
capitals indicate the substituted sequences.)  
 Transient transfection into Huh7 cells was performed using a cationic lipid 
method employing Tfx-20 (Promega), according to the manufacturer’s 
instructions. PON1 plasmid DNA (0.4 µg per well) was cotransfected with the 
pRL-TK vector (Promega) (0.2 µg per well), which expressed Renilla luciferase 
as an internal control. Cell extracts were prepared at 24 h for the luciferase 
activity assay. Both firefly and Renilla luciferase activities in the cell lysates were 
measured using the Dual-Luciferase® Reporter Assay System (Promega) 
according to the manufacturer’s instructions. Promoter activities were expressed 
as firefly luciferase activity divided by Renilla luciferase activity. Six wells were 
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used for each transfection condition. Each examination was repeated at least 
three times, and representative results are shown. 
 
Cell lysis and Western blotting 
 Huh7 cells were grown to confluence, harvested, and lysed as described 
previously [23]. The protein concentration was adjusted (Bio-Rad Protein Assay, 
Bio-Rad, Hercules, CA). Western blotting was performed as described 
previously [23]. Antibodies for PON1 [8], α-tubulin (Sigma), p44/42 MAP kinase, 
phospho-p44/42 MAP kinase, SAPK/JNK, phospho-SPAK/JNK, p38 MAP kinase 
and phospho-p38 MAP kinase (all from Cell Signaling, Beverly, MA) were used. 
The bands were made visible by enhanced chemiluminescence detection 
reagents (Amersham Pharmacia Biotech, Arlington Heights, IL). Each 
experiment was repeated at least three times, and representative results are 
shown. 
 
Preparation of nuclear extracts and electrophoretic mobility shift assay 
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(EMSA) 
 Huh7 cells were grown to confluence and harvested, and the nuclear 
fraction was isolated and extracted as described previously [16, 23]. EMSA was 
performed as described previously [16, 23]. The synthetic sense and antisense 
strands of oligonucleotides (-187/-159) were 5’- 
GGTGGGGGCTGACCGCAAGCCGCGC-3’ and 
5’-GGCGCGGCTTGCGGTCAGCCCCCAC-3’, respectively. For a supershift 
study, Sp1-specific polyclonal antibody (PEP2) (Santa Cruz Biotechnology, 
Santa Cruz, CA) was used. The dried gel was analyzed by a computerized 
system for radioluminography (BAS2500, Fuji Photo Film, Kanagawa, Japan) 
and for analyzing software (MacBAS version 2.3, Fuji Photo Film). The 
intensities of bands were compared by using the software. Each experiment was 
repeated at least three times, and representative results are shown. 
 
Statistical analysis 
 Comparisons for two groups were performed using the Tukey–Kramer test. 
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Statistical differences among three groups or more were determined by analysis 
of variance (ANOVA). P values <0.05 were considered statistically significant. 
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RESULTS 
Effects of pitavastatin on PON1 promoter activity and PON1 protein 
expression  
 We previously reported that pitavastatin enhanced the promoter activity of 
PON1 gene in HepG2 cells using a reporter gene assay method and that we 
could detect PON1 mRNA but not PON1 protein in HepG2 cells [22]. Huh7 is 
another human hepatoma cell line and expresses PON1 protein. Consequently, 
in the present study we examined the effects of pitavastatin on PON1 promoter 
activity and PON1 protein expression in Huh7 cells. PON1 promoter activity was 
significantly increased dose-dependently by pitavastatin from 5 to 50 µM 
(relative promoter activity; 1.0 ± 0.1 at pitavastatin 0 μM, 1.6 ± 0.1 at 5 μM, 1.6 ± 
0.1 at 10 μM, 1.7 ± 0.1 at 20 μM and 1.9 ± 0.1 at 50 μM). PON1 protein 
expression was increased dose-dependently by pitavastatin from 0.1 to 10 µM in 
Huh7 cells after 24 h. 
 
Effects of pitavastatin on MAP kinase signaling cascades  
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 We examined the effects of pitavastatin on the activation of p44/42 MAP 
kinase signaling cascade, using immunoblotting in Huh7 cells through 120 min 
(Fig 1A). Pitavastatin 10 µM phosphorylated p44/42 MAP kinase after 5 min, and 
this effect was bolstered for 60 min. Pitavastatin 0.1–20 µM dose-dependently 
effected on the phosphorylation of p44/42 MAP kinase in 60 min incubation (Fig 
1B). On the other hand, 10 µM pitavastatin affected neither the phosphorylation 
of SAPK/JNK nor p38 MAP kinase (Fig 1C and 1D).  
 
Role of MAP kinase signaling cascades in pitavastatin-enhanced PON1 
promoter activation  
 We examined which pathway in the MAP kinase signaling cascades was 
involved in pitavastatin-induced PON1 promoter activation in Huh7 cells. Each 
specific inhibitor of MAP kinase signaling cascades was added to cell cultures 2 
h after plasmid transfection. PON1 promoter activity was measured at 24 h after 
treatment. Both 10 µM PD98059 (MAP kinase kinase I inhibitor) and 10 µM 
U0126 (MAP kinase kinase inhibitor) attenuated the pitavastatin-induced 
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increase in promoter activity (Fig 2A and 2B). Neither SP600125 (SAPK/JNK 
inhibitor) nor SB203580 (p38 MAP kinase inhibitor) abolish the 
pitavastatin-induced increase in promoter activity (Fig 2C and 2D).   
 
Role of p44/42 MAP kinase signaling cascade in pitavastatin-enhanced 
PON1 protein expression 
 Because the phosphorylation of p44/42 MAP kinase was related to the 
pitavastatin-induced activation of PON1 promoter, we studied whether the 
pitavastatin-induced phosphorylation of p44/42 MAP kinase was an influence on 
the PON1 protein expression in Huh7 cells (Fig 3). The PON1 protein expression 
in Huh7 cells was significantly increased by 10 µM pitavastatin (p<0.05), though 
5µM PD98059 abolished this effect after 24 h (Fig 3A and 3B).  
 
Role of Sp1 in pitavastatin-enhanced PON1 promoter activation  
 We examined the relationship of Sp1 to PON1 promoter activity in Huh7 
cells. An overexpression of Sp1 significantly increased the PON1 promoter 
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activity in Huh7 cells (relative promoter activity; 17.8 ± 0.5 (control 1.0 ± 0.4, 
p<0.0001)). However, 50 nM mithramycin, an Sp1 inhibitor, almost attenuated 
pitavastatin-enhanced PON1 promoter activity.  
 
Role of SREBP-2 phosphorylation in pitavastatin-enhanced PON1 
promoter activation  
 Next we studied the relationship between SREPB-2 phosphorylation and 
pitavastatin-enhanced PON1 promoter activation in Huh7 cells. The construct 
with PON1 promoter was transfected, and the mutated SREBP-2 expression 
plasmid (pCL-SREBP-2 S432/455A) or an empty vector was simultaneously 
cotransfected. Pitavastatin-enhanced PON1 promoter activity was attenuated by 
cotransfection with PCL-SREBP-2 S432/455A (Fig 4).  
 
Role of p44/42 MAP kinase signaling cascade in Sp1 binding to PON1 DNA 
in Huh7 cells 
 Finally, we investigated whether pitavastatin-induced phosphorylation of 
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p44/42 MAP kinase was associated with the binding of Sp1 to DNA fragments of 
the PON1 gene promoter (-187/-159), since pitavastatin enhanced PON1 
promoter activation through Sp1. An EMSA showed Sp1-DNA complex bands, 
which were attenuated following an addition of the competitors and supershifted 
with the addition of the anti-Sp1 antibodies (Fig 5A). Treatment with 50 µM 
pitavastatin increased the band intensity of Sp1-DNA complex (p <0.01). 
Pretreatment with 10 µM PD98059 abolished the pitavastatin-increased band 
intensity (Fig. 5B).  
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DISCUSSION 
 In the present study, pitavastatin affected PON1 gene promoter activity and 
PON1 protein expression through the activation of the MAP kinase signaling 
cascades in Huh7 cells. To the best of our knowledge, our result of p44/42 MAP 
kinase activation by pitavastatin is the first report. Further, we showed that 
pitavastatin induced phosphorylation of p44/42 MAP kinase without affecting 
either phosphorylation of SAPK/JNK or p38 MAP kinase among the MAP 
signaling cascades.  
 Three major MAP kinases, which were p44/42 MAP kinase, SAPK/JNK, 
and p38 MAP kinase, are generally recognized as being the central elements of 
intracellular signaling in mammalian cells [24, 25]. Many recent reports have 
shown that statins cause not only activation, but also an inhibition of various 
MAP kinase signaling cascades [19-21, 26]. The present study shows that 
pitavastatin activates p44/42 MAP kinase cascade, a classical MAP kinase 
pathway. Some recent studies showed that statins stimulated to release vascular 
endothelial factor in vascular smooth muscle cells (VSMC), induced 
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cycloxygenase-2 gene expression in macrophages, or promoted HDL-induced 
prostacyclin release in VSMC, all of which were carried through the activation of 
p44/42 MAP kinase cascade [19-21]. On the other hand, another study of 
different cell systems showed that pitavastatin inhibited the activation of major 
MAP kinases induced by C-reactive protein [26]. The differences of both the cell 
types and stimulation conditions may determine the outcome of MAP kinase 
signaling cascades and may be responsible for incompatible function on the 
stimulating cells.  
 It has been in no reports that PON1 was controlled through MAP kinase 
signaling cascades. Our results showed that specific inhibitors of the p44/42 
MAP kinase signaling cascade had a suppressive effect on 
pitavastatin-stimulated PON1 promoter activity and PON1 protein expression. 
On the other hand, inhibitors of SAPK/JNK or p38 MAP kinase signaling 
cascade did not affect pitavastatin-stimulated PON1 promoter activity. These 
results suggest that pitavastatin enhances PON1 promoter activity and PON1 
protein expression through the phosphorylation of p44/42 MAP kinase in Huh7 
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cells. PON1 may be controlled through specific phospholylation of p44/42 MAP 
kinase in response not only to statin, but also to other extracellular stimulations 
that were yet detected.  
 SREBP-2 has constitution of the cytosolic N-terminal segment including 
the basic helix-loop-helix leucine zipper (bHLHZ) domain and the C-terminal 
regulatory segment interacting with the SREBP cleavage-activating protein. The 
N-terminal domain of SREBP-2 can be cleaved and translocated into the 
nucleus, followed by activating transcription factors that bind to sterol-responsive 
elements not only in the LDL receptor gene but also in many other genes coding 
for enzymes involved in cholesterol metabolism. Moreover, SREBP-2 has 
p44/42 MAP kinase specific phosphorylation sites that did not influence 
protein-DNA interaction [17, 18]. Consequently, we constructed two expression 
vectors of the mutated form of the SREBP-2 to investigate whether pitavastatin 
accelerated PON1 gene promoter transcription through SREBP-2 activation in 
Huh7 cells. One is a construct with mutated bHLHZ in the N-terminal domain of 
SREBP-2 (pCL-SREBP-2 L380/387/394A), and the other is a construct with 
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mutated p44/42 MAP kinase specific phosphorylation sites in the N-terminal 
domain of SREBP-2 (pCL-SREBP-2 S432/455A) [18]. Pitavastatin could not 
enhance PON1 promoter activity simultaneously cotransfected with 
pCL-SREBP-2 L380/387/394A in Huh7 cells (data not shown). Therefore we 
considered that pitavastatin increased PON1 promoter activity through the 
acceleration of SREBP-2-DNA binding. This result was consistent with a 
previous report [15]. On the other hand, pCL-SREBP-2 S432/455A inhibited 
pitavastatin-enhanced PON1 promoter activity in Huh7 cells (Fig 4). The result 
supposed pitavastatin influenced PON1 promoter activity through SREBP-2 
which is phosphorylated by p44/42 MAP kinase. The phosphorylations at 
S432/455A of SREBP-2 were already reported to have no influence on DNA 
interaction, but they increased its transactivity [18]. Therefore we suggested that 
pitavastatin-phosphorylated SREBP-2 through p44/42 MAP kinase might 
influence other transcription factors or cofactors that are important for the 
function of SREBP-2, for example Sp1, which follows by pitavastatin-increased 
PON1 promoter activity.  
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 Sp1 is a ubiquitous transcription factor and also reportedly activate PON1 
gene transcriptions [23, 27]. We also showed that PON1 gene promoter 
transcription was associated with Sp1 in this study. Moreover, EMSA results 
showed that the binding intensity of Sp1 to DNA fragments of PON1 promoter 
was increased by treatment with pitavastatin and that PD98059 attenuated 
pitavastatin-increased band intensity of the Sp1-DNA complex (Fig 5). These 
results suggest that pitavastatin activates PON1 transcription through 
phosphorylation of p44/42 MAP kinase, which increases Sp1-DNA binding. 
 In conclusion, pitavastatin may phosphorylate SREBP-2 and/or increase 
the binding of Sp1 to the PON1 gene promoter region through the 
phosphorylation of p44/42 MAP kinase, and pitavastatin increases PON1 gene 
transactivation and PON1 protein expression through those mechanisms.  
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FIGURE LEGENDS 
Figure 1. The effect of pitavastatin on the phosphorylation of p44/42 MAP kinase, 
SAPK/JNK, or p38 MAP kinase in Huh7 cells.  
Cultured cells were stimulated with 10 µM pitavastatin for time course studies (A, 
C, and D) and with various concentrations of pitavastatin at 60 min in a 
dose-dependent study (B). 
 
Figure 2. Effect of specific inhibitors of MAP kinase signaling cascades on 
pitavastatin-enhanced PON1 promoter activation in Huh7 cells.  
pGL3-PON1 (–587/–6) plasmid was transfected into Huh7 cells and treated with 
50 µM pitavastatin and 10µM various specific inhibitors of MAP kinase signaling 
cascades PD98059 (A), U0126 (B), SP600126 (C) and SB203580 (D). 
 
Figure 3. Effects of PD98059 on pitavastatin-increased PON1 protein expression 
in Huh7 cells.  
Cultured cells were incubated with or without 5 µM PD98059 at 60 min after 
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stimulation with 10 µM pitavastatin. Immunoblotting was performed with antibody 
to PON1 or α-tubulin (A). Relative PON1 protein expressions (PON1/α-tubulin) 
were calculated (B).  
 
Figure 4. The relationship of SREBP-2 phosphorylation to pitavastatin-enhanced 
PON1 promoter activation in Huh7 cells.  
pGL3-PON1 (–587/–6) plasmid was transfected into Huh7 cells, and the mutated 
SREBP-2 expression plasmid (PCL-SREBP-2 S432/455A) or an empty vector 
was simultaneously cotransfected, and then each were treated with or without 50 
µM pitavastatin.  
 
Figure 5. Effect of p44/42 MAP kinase signaling cascade on the binding of Sp1 
to the PON1 gene upstream (-187/-159) in Huh7 cells.  
The Sp1-DNA complex band (∗) was supershifted after the addition of the 
anti-Sp1 antibodies (∗∗) and disappeared following an addition of competitor (A). 
Relative band intensities of the complexes with DNA fragments and Sp1 were 
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calculated (B).   
 







